Dear Clinician:

Welcome to Dana-Farber Master Class for Oncologists, continuing education for practicing oncologists that’s focused on clinically relevant, practice and patient-care issues from internationally recognized experts.

The educational content for the Dana-Farber Master Class for Oncologists initiative was created by Drs. Mayer, Burstein, Freedman, and Johnson and the entire faculty team. This content is informed by current, comprehensive needs assessment, yielding timely sessions designed to support your patients’ diagnoses, treatment, and management. The feedback we get from you over the next 2 days will inform the educational design of future programs.

We have purposefully designed an intimate program to support clinical and therapeutic exchange. Our goal is to give you a complete and targeted educational experience, one that lets you make informed decisions with greater confidence and deliver the highest levels of quality care. Last year’s attendees described Master Class as “intense,” “time efficient,” “innovative,” “engrossing”, and “practice-changing.” We welcome your feedback and questions and encourage you to participate in the audience response portion of this activity.

For your convenience, printer-friendly copies of the session slides will be available for you to view and download. Visit www.dana-farber.pri-med.com/47MIA09A/syllabus to download the session slides. Materials will be available for you up until one year after the program date.

Our commitment to you does not end after these two days. We have designed online education to support your experience here. Log onto www.dana-farber.pri-med.com to access education that is relevant to you.

Thank you for joining us at Dana-Farber Master Class for Oncologists. We look forward to meeting you and hearing your input throughout the program. If you have any questions, please visit us on the Web at www.dana-farber.pri-med.com or share your feedback via e-mail at dana-farber@pri-med.com.

Sincerely,

Robert J. Mayer
Course Chair, Master Class for Oncologists
Faculty Vice President for Academic Affairs
Dana-Farber Cancer Institute
Stephen B. Kay Family Professor of Medicine
Harvard Medical School

Frank Britt
CEO, M|C Holdings Corp.
Owner of M|C Communications and the Pri-Med Brand

Marissa Seligman, PharmD
Chief Clinical & Regulatory Affairs Officer & Senior Vice President
Pri-Med Institute

Dana-Farber Master Class for Oncologists is accredited by Pri-Med Institute
101 Huntington Avenue, Boston, MA 02199 | 877.477.4633 | www.dana-farber.pri-med.com
L E A R N E R  B I L L  O F  R I G H T S

Pri-Med Institute recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill, or performance. As part of Pri-Med Institute’s duty to you as a learner, you have the right to expect that your continuing medical education experience will include:

**Content** that:

- Is driven and based on independent survey and analysis of learner needs
- Promotes improvements or quality in health care
- Is current, valid, reliable, accurate, and evidence-based
- Offers balanced presentations that are free of commercial bias for, or against, a product/service
- Is vetted through a process that resolves any conflicts of interests of planners and faculty
- Is driven and based on learning needs, not commercial interests
- Addresses the stated objectives or purpose
- Is evaluated for its effectiveness in meeting the identified educational need

A **learning environment** that:

- Is based on adult learning principles that support the use of various modalities
- Supports learners’ ability to meet their individual needs
- Respects and attends to any special needs of the learners
- Respects the diversity of groups of learners
- Is free of promotional, commercial, and/or sales activities

**Disclosure of**:

- Relevant financial relationships planners, teachers, and authors have with commercial interests related to the content of the activity
- Commercial support (funding or in-kind resources) of the activity
Friday, December 18, 2009

To access the full set of presented slides, please visit www.dana-farber.pri-med.com/47MIA09A/syllabus. Click on the individual session links in order to print as needed. The slides will be available for up to one year following today's program.

6:15 - 7:15 AM   Registration and Continental Breakfast

7:15 - 7:30 AM   Opening Remarks

7:30 AM - 12:15 PM   TRACK 1: HEMATOLOGIC MALIGNANCIES

7:30 - 8:15 AM   Session 1: Recent Advances in the Understanding and Treatment of Acute Leukemia and Myelodysplastic Syndromes
Richard M. Stone, MD

8:15 - 9:00 AM   Session 2: Chronic Myelocytic Leukemia: Imatinib and Beyond
Daniel J. DeAngelo, MD, PhD

9:00 - 9:15 AM   Networking Break

9:15 - 10:00 AM   Session 3: Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes
Ayalew Tefferi, MD

10:00 - 10:45 AM   Session 4: Lymphomas: Optimizing Therapeutic Choices for Initial Management
Arnold S. Freedman, MD

10:45 - 11:00 AM   Networking Break

11:00 - 11:45 AM   Session 5: Multiple Myeloma: Current Treatment Paradigms and Future Directions
Kenneth C. Anderson, MD

11:45 AM - 12:15 PM   Hematologic Malignancies Panel Discussion

12:15 - 1:00 PM   Complimentary Lunch

1:00 - 5:45 PM   TRACK 2: BREAST CANCER

1:00 - 1:45 PM   Session 1: Towards Personalized Medicine in Breast Cancer: Understanding Molecular Subtypes and the Role of Diagnostics
Lisa A. Carey, MD

1:45 - 2:30 PM   Session 2: Genetic Testing in Breast Cancer: Appropriate Patient Selection and Implications for Management
Judy E. Garber, MD, MPH

2:30 - 2:45 PM   Networking Break

2:45 - 3:30 PM   Session 3: HER2 + Breast Cancer: Current Best Practices and Future Directions
Eric P. Winer, MD

3:30 - 4:15 PM   Session 4: Adjuvant Endocrine Therapy: Therapeutic Choices and Factors Affecting Recurrence in Hormone Receptor–Positive Breast Cancer
Harold J. Burstein, MD, PhD

4:15 - 4:30 PM   Networking Break

4:30 - 5:15 PM   Session 5: Breast Cancer Survivorship: Optimizing Patient Follow-up for Recurrence and Long-term Effects of Therapy
Ann H. Partridge, MD, MPH

5:15 - 5:45 PM   Breast Cancer Panel Discussion

5:45 - 6:15 PM   Networking Break and Complimentary Light Refreshments

6:15 - 6:45 PM   Comparative Effectiveness in Oncology Practice
Deborah Schrag, MD, MPH
Saturday, December 19, 2009

To access the full set of presented slides, please visit [www.dana-farber.pri-med.com/47MIA09A/syllabus](http://www.dana-farber.pri-med.com/47MIA09A/syllabus). Click on the individual session links in order to print as needed. The slides will be available for up to one year following today’s program.

6:15 - 7:15 AM  
Registration and Continental Breakfast

7:15 - 7:30 AM  
Opening Remarks

7:30 AM - 12:15 PM  TRACK 3: GASTROINTESTINAL CANCERS

7:30 - 8:15 AM  
Session 1: Update on Esophagogastric Cancers: Weighing the Therapeutic Options  
Peter C. Enzinger, MD

8:15 - 9:00 AM  
Session 2: Pancreatic and Hepatobiliary Cancers: Progress at Last?  
Alan P. Venook, MD

9:00 - 9:15 AM  
Networking Break

9:15 - 10:00 AM  
Session 3: Diagnosis, Genetics, and Management of Hereditary Gastrointestinal Cancers  
Sapna Syngal, MD, MPH

10:00 - 10:45 AM  
Session 4: Reducing Risk of Colorectal Cancer: Current Evidence on Dietary, Lifestyle, and Other Factors  
Charles S. Fuchs, MD, MPH

10:45 - 11:00 AM  
Networking Break

11:00 - 11:45 AM  
Session 5: Advances in the Systemic Treatment of Colorectal Cancer  
Robert J. Mayer, MD

12:15 - 1:00 PM  
Complimentary Lunch

1:00 - 5:45 PM  TRACK 4: LUNG, HEAD, AND NECK CANCERS

1:00 - 1:45 PM  
Session 1: Innovations in the Surgical Treatment of Lung Cancer  
Scott J. Swanson, MD

1:45 - 2:30 PM  
Session 2: Primary Treatment of Non-Small Cell Lung Cancer: Individualized Management by Cancer Stage  
Mark G. Kris, MD

2:30 - 2:45 PM  
Networking Break

2:45 - 3:30 PM  
Session 3: Improved Strategies for Relapsed NSCLC: New Regimens, New Combinations, and Targeted Therapies  
Pasi A. Jänne, MD, PhD

3:30 - 4:15 PM  
Session 4: Small Cell Lung Cancer: Best Practices and Recent Advances  
Bruce E. Johnson, MD

4:15 - 4:30 PM  
Networking Break

4:30 - 5:15 PM  
Session 5: Head and Neck Cancer: Update on Comprehensive Management  
David G. Pfister, MD

5:15 - 5:45 PM  
Lung, Head, and Neck Cancers Panel Discussion

Sessions with this symbol have related Online activities. See full list following agenda or visit [www.dana-farber.pri-med.com](http://www.dana-farber.pri-med.com) to reinforce your learning and earn additional CME credits.

[Please note that session titles and speaker names were current at time of syllabus printing deadline.]
HEMATOLOGIC MALIGNANCIES ONLINE ACTIVITIES

**Acute Myeloid Leukemia: Impact of Genetics on Prognosis**
Cytogenic analysis, or karyotyping, is used to determine prognosis and treatment in patients with acute myeloid leukemia (AML). Controversy exists over optimal postremission treatment for patients in the intermediate-risk group, most of whom have normal cytogenetics. Dr. Richard Stone reviews new data on additional genetic mutations that could guide treatment decisions for these patients.


**Chronic Myelocytic Leukemia: Imatinib and Beyond**
In recent years, tyrosine kinase inhibitors (TKIs), particularly imatinib, have led to dramatic improvements in the survival of patients with chronic myelocytic leukemia (CML). Dr. Daniel DeAngelo provides an expert’s insight into the latest data and thinking on the use of imatinib and other TKIs for CML.


**JAK2 Inhibitors as Emerging Therapies for Myeloproliferative Neoplasms**
The myeloproliferative neoplasms are a group of hematological malignancies that are characterized by overproduction and extended survival of 1 or more myeloid cell types. They include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), and a number of other disorders. Dr. Ayalew Tefferi provides an expert’s perspective on the role of Janus kinase 2 (JAK2) in the diagnosis of myeloproliferative disorders and on recent progress towards the development of JAK2 inhibitors.


**Current and Emerging Options for Initial Treatment of Multiple Myeloma**
The initial approach to myeloma patients has been transformed in the last 5 years. Dr. Kenneth Anderson of the Dana-Farber Cancer Institute provides an expert’s perspective on current and emerging options for initial treatment of multiple myeloma.


**Multiple Myeloma: Current Treatment Paradigms and Future Directions**
Your next patient is a 43-year old patient with multiple myeloma who had complete response to initial treatment with thalidomide dexamethasone followed by high dose melphalan and autologous stem cell transplant, but has now relapsed. How comfortable do you feel managing this patient? Dr Kenneth Anderson of the Dana Farber Cancer Institute discusses the options for managing this challenging patient as well as looking at what treatment options are on the horizon.

Reinforce your learning and earn additional credits by completing these related Online CME activities

BREAST CANCER ONLINE ACTIVITIES

- **Breast and Ovarian Cancer Genetics: Current Status and Future Directions**
  What role do hereditary BRCA1 and BRCA2 mutations play in breast and ovarian cancer etiology, prevalence, risk, prognosis, screening, and treatment? Dr. Judy Garber provides an expert's perspective on recent findings and their applicability to different types of breast cancer patients.

- **Recurrent Triple-Negative Breast Cancer: Therapeutic Options and Prognosis**
  Breast cancer subtype (as defined by presence or absence of particular molecular markers) has considerable significance for a patient's treatment response and prognosis. Dr. Lisa Carey, Medical Director of the UNC Breast Center, provides an expert's perspective on therapeutic options and prognosis for patients with triple-negative breast cancer.

- **HER2-Positive Breast Cancer: What to Expect in the Next Five to Ten Years**
  Variable patient responses to trastuzumab, the first targeted therapy for HER2-positive breast cancer, has suggested that there are subtypes within the HER-2-positive class of breast cancers. Drs. Eric Winer and Clifford Hudis share expert insights into the current state of knowledge and standard of care for HER2-positive breast cancer in various settings.

- **Treatment of HER2 Positive Breast Cancer**
  The treatment of HER-2 positive breast cancer has changed dramatically in the last 10 years and survival in advanced disease has improved. However, resistance to treatment inevitably develops with current treatments. How comfortable are you in managing these complex patients? Join our Dana Farber faculty for an interactive session on the treatment of HER-2 positive breast cancer.

- **Best Practices for the Management of Breast Cancer Survivors: Current Recommendations for Screening and Diet**
  How should breast cancer survivors, who are at increased risk for new or recurrent cancer, be followed? Can lifestyle or other interventions reduce this risk? Dr. Ann Partridge of the Breast Oncology Center at the Dana-Farber Cancer Institute provides an expert's perspective on 2 possible interventions, MRI surveillance and dietary fat restriction.
Reinforce your learning and earn additional credits by completing these related Online CME activities

**BREAST CANCER ONLINE ACTIVITIES**

Emerging Legal and Ethical Issues Surrounding Genetics and Genomics in Oncology
The past two decades have seen a rapid expansion in the knowledge of the underlying genetics of familial cancer syndromes, allowing for the development of genetic tests for predispositions to a wide range of malignancies. Dr. Kenneth Offit provides an expert’s perspective on current issues in genetic testing for cancer susceptibility, including ethical and legal considerations, the role of genomic risk profiles, and the use of assisted reproductive technology by patients with inherited cancer risks.

Early-stage Endocrine-responsive Breast Cancer: Investigating New Options for Premenopausal Women
Although two-thirds of early-stage breast cancers in premenopausal women are endocrine responsive, high levels of estrogen produced by still-functioning ovaries can complicate treatment. A recent study compared ovarian suppression plus either tamoxifen or an aromatase inhibitor (AI) (an off-label use) in this setting. In addition, the effect of adding a bisphosphonate to the endocrine therapy (also an off-label use) was also studied. Dr Harold Burstein provides an expert’s perspective on the findings and their potential clinical implications.
Reinforce your learning and earn additional credits by completing these related Online CME activities

GASTROINTESTINAL CANCERS ONLINE ACTIVITIES

Gastroesophageal Cancers: Examining Current Evidence for Chemotherapeutic Options
Perioperative chemotherapy is a part of managing patients with resectable adenocarcinomas of the lower esophagus, gastroesophageal junction, and upper stomach. Dr Peter Enzinger provides an expert’s perspective on the results of the MAGIC trial, which assessed whether adding a perioperative regimen of epirubicin, cisplatin, and infusional 5-fluorouracil (ECF) to surgery improved outcomes among patients with resectable, potentially curable gastric cancer, and the ACCORD07 trial, which was designed to evaluate the impact on survival of 2 to 3 cycles of preoperative fluorouracil-cisplatin (FP) in resectable adenocarcinoma of the stomach and lower esophagus.
www.pri-med.com/activity/129807

Pancreatic and Hepatobiliary Cancers: Progress at Last?
Treatment options are extremely limited in pancreatic and hepatobiliary cancers, and many tumors are identified only at an advanced stage, making these conditions extremely challenging to treat. Join Dr. Alan Venook, a nationally renowned expert in colorectal and liver cancers, for a stimulating presentation on current standards of care for these cancers, and a review of the latest data from around the world.
www.pri-med.com/activity/134049

Hepatocellular Carcinoma: Progress at Last
For years, there have been no effective systemic therapies for hepatocellular cancer and very few were even studied. Now the first agent has been found that can help patients with this disease by inhibiting the B-raf oncogenic signaling pathway. Dr. Alan Venook offers an expert’s perspective on the agent, sorafenib, and the SHARP trial in which demonstrated its efficacy was demonstrated.
www.pri-med.com/activity/131072

Hereditary Gastrointestinal Cancers: Insights Into Management for the Practicing Oncologist
How does heredity enter into management of gastrointestinal (GI) cancers (ie, cancers of the colon, rectum, pancreas, and stomach)? Dr. Sapna Syngal explains when and how oncologists should suspect the presence of a hereditary syndrome in their patients with GI cancers, how confirmation thereof alters clinical decisionmaking during treatment and follow up, and what this finding implies for other family members.
www.pri-med.com/activity/128568

Effects of Diet and Lifestyle After Colon Cancer Has Been Diagnosed: What Should We Tell Our Patients?
Evidence suggests that diet and other lifestyle factors have considerable influence on the risk of developing colon cancer. Patients with colon cancer are often aware of this link and frequently ask their advice on these matters during the course of their treatment. Dr Charles Fuchs provides an expert perspective on the effect of diet on overall survival of colon cancer.
www.pri-med.com/activity/131259
LUNG, HEAD, AND NECK CANCERS ONLINE ACTIVITIES

New Surgical Techniques and Other Emerging Modalities for Treating Early-Stage Lung Cancer
Lung cancer rates are currently declining in the United States, but still account for an estimated 31% of cancer deaths among men and 26% of cancer deaths among women in 2008. New techniques such as minimally invasive surgery, stereotactic radiosurgery, radiofrequency ablation, and brachytherapy are feasible, but in many cases their long-term efficacy is still unknown. This Expert Perspective discusses new treatment modalities, the current status of clinical trials and information on adjuvant chemotherapy for early-stage lung cancer, a subject of some debate in recent years.
www.pri-med.com/activity/130650

Personalizing the Initial Therapy of Advanced Non-Small-Cell Lung Cancer (NSCLC)
In patients with advanced non-squamous cell lung cancer (NSCLC), although chemotherapy has been the standard of care, the targeted agent bevacizumab shows particular promise. Dr. Mark Kris provides an expert's perspective on 2 recent clinical trials that enhance our understanding of how bevacizumab can be used in these patients and how pathological tumor features affect treatment response, with significant implications for clinical practice.
www.pri-med.com/activity/134252

Primary Treatment of Non-Small Cell Lung Cancer
Three decades of chemotherapy have made progress in the primary treatment of non small cell lung cancer (NSCLC). However, there is a significant need for improved management strategies including new regimens and the use of targeted and personalized therapies. Join an interactive webcast that discusses the current research into this often fatal disease and benefit from the management recommendations of our expert faculty.
www.pri-med.com/activity/134832

Improved Strategies for Relapsed NSCLC: New Regimens, New Combinations, and Targeted Therapies
In many clinical trials advanced non-small cell lung cancer has a mean survival of 8 to 11 months. There is a significant need for improved management strategies including new regimens, new combinations of regimens and the use of targeted therapies. Join an interactive webcast that discusses the current research into this fatal disease and benefit from the management recommendations of our Dana Farber expert faculty.
www.pri-med.com/activity/132833

The Role of EGFR in Lung Cancer: Molecular Diagnostics and Therapeutic Choices
Signaling pathways activated by the epidermal growth factor receptor (EGFR) have been implicated in the etiology of many cancers, including lung, colon, head and neck, and pancreatic cancers. Dr Jänne provides us with an expert's perspective on the role of EGFR mutations and other molecular markers in patient selection for EGFR-targeted therapies.
www.pri-med.com/activity/131021

Multimodal Approaches to Locally or Regionally Advanced Head and Neck Cancers: The Role of Induction Chemotherapy
Curative-intent treatment for squamous cell head and neck cancers has evolved to include chemotherapy in addition to surgery and radiation. Dr. David Pfister reviews current evidence on the role of induction chemotherapy in locoregionally advanced head and neck cancers and offers an expert view on how to apply it clinical practice.
www.pri-med.com/activity/136297
The Cost of Cancer Care: Issues Facing Oncologists and Their Patients
Cancer care is tremendously expensive in the US. Increasingly, as patients are being required to bear more of this cost and to pay up front, community oncologists have to address financial issues with patients and families who face life-threatening illness. Dr. Deborah Schrag offers an expert’s perspective.
www.pri-med.com/activity/133726
Dana-Farber Cancer Institute gratefully acknowledges the following organizations for providing educational grants or financial support at the time of print for this activity. Any additional support will be disclosed by the activity moderator at the start of the educational activity and made available in print at the registration table:

**Distinguished Supporters:**
Genentech BioOncology and OSI Oncology
Millennium, the Takeda Oncology Company

**Supported by an educational grant from**
Genentech BioOncology and OSI Oncology

**Leadership Supporters:**
sanofi-aventis, Eli Lilly and Celgene

This program is supported by an educational grant from sanofi-aventis U.S.

**Major Supporters:**
Ortho-Biotech Oncology, Eisai, AstraZeneca, and Bristol-Myers Squibb & ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.

**Supported by an educational grant from**
Genentech BioOncology and Biogen Idec.
Dana-Farber Master Class for Oncologist programs are designed and executed by Dana-Farber Cancer Institute and M|C Communications, LLC located in Boston, MA. Pri-Med Institute, the clinical education division of M|C Holdings Corporation, is the education sponsor responsible for accrediting this program.

Dana-Farber Cancer Institute
Our goal is to improve cancer patient care worldwide via our commitment to education. The design of the content for Dana-Farber Master Class was led by Dr. Robert J. Mayer and the expert faculty representing Dana-Farber Cancer Institute and other leading clinical and academic centers of excellence. The content design has been informed by in-depth needs assessments and expert insights into the most cutting-edge discoveries in the understanding, management, and medical treatment of various forms of cancer.

Pri-Med Institute
Dana-Farber Cancer Institute has partnered with Pri-Med Institute to deliver high-quality credited learning experiences for participants and faculty speakers. Pri-Med Institute is accredited by the ACCME and ACPE and approved as a provider of contact hours by the AANP and ANCC.

Dana-Farber Master Class Track Directors Financial Disclosure
Dr Robert J. Mayer has no relationships to disclose.
Dr Arnold S. Freedman has no relationships to disclose.
Dr. Harold J. Burstein has no relationships to disclose.
Dr Bruce E. Johnson serves as a consultant and receives patent honoraria from Genzyme.

Pri-Med Institute Medical Advisory Board Financial Disclosure
George Mejicano, MD, has nothing to disclose.
Victor Diaz, MD, has nothing to disclose.
Stephen Goldfinger, MD, has nothing to disclose.
Michael Bloch, MD, is a member of speakers’ bureaus for AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc., and sanofi-aventis US, and receives research support from AstraZeneca Pharmaceuticals LP and Novartis Pharmaceuticals Corporation. He also receives honorarium from Pfizer Inc. and sanofi-aventis U.S.

PMI Clinical Staff and Tufts Health Care Institute Peer Reviewer Financial Disclosure
As a continuing medical education provider accredited by the ACCME, it is the policy of Pri-Med Institute to require any individual in a position to influence educational content to disclose the existence of any financial interest or other personal relationship with the manufacturer(s) of any commercial product(s). Pri-Med clinical staff and Tufts Health Care Institute expert content reviewers have no financial disclosure or conflicts of interest to resolve for each of the sessions related to this activity.

Conflict of Interest Resolution Statement
When individuals in a position to control content have reported financial relationships with one or more commercial interests, as listed above, Pri-Med Institute works with them to resolve such conflicts to ensure that the content presented is free of commercial bias. The content of this presentation was vetted by the following mechanisms and modified as required to meet this standard:

- Content peer review by external topic expert
- Content validation by external topic expert and internal Pri-Med Institute clinical editorial staff

© 2009 M/C Communications, LLC. All other trademarks are the property of their respective owners.
General Information

The Dana-Farber Cancer Institute Master Class for Oncologists is designed to provide a comprehensive review for practitioners of the clinical and pathophysiological basis for the diagnosis and treatment of lung and breast cancers, as well as gastrointestinal and hematologic malignancies. Primary emphasis will be placed on the broad area of medical management. Recent advances in genetics, clinical pharmacology, epidemiology, and supportive care will be stressed.

At the conclusion of this class, the participant will be able to:

- Appreciate the use of genetics as a means of defining families at high risk for the development of cancer.
- Understand recent advances in the management of cancer and associated disorders
- Choose among multidisciplinary management options in lung and breast cancers, and gastrointestinal and hematologic malignancies
- Apply these principles to his/her individual practice

More detailed learning objectives can be found in the individual Track’s section of this syllabus. We encourage you to discuss patient care practices with your colleagues and the expert faculty to have the greatest impact on your experience. This program is accredited by Pri-Med Institute.

Accreditation Statement:
Pri-Med Institute. Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement:
Pri-Med Institute designates this educational activity for a maximum of 17.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Academic Partnership:
Pri-Med Institute gratefully acknowledges Tufts Health Care Institute as academic partners in review of the educational content.

Disclosure Policy:
It is the policy of the Pri-Med Institute to ensure balance, independence, objectivity and scientific rigor in all its sponsored educational programs. All faculty participating in the sponsored programs are expected to disclose to the program audiences any real or apparent conflict(s) of interest related to the content of their presentation(s).

Off-Label/Investigational Disclosure:
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication being discussed. Faculty have been instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, the specific slide will include disclosure of the off-label or investigational agent being discussed. Views presented during this program related to unapproved uses of products are solely those of the presenter and are not endorsed by Pri-Med Institute.

Financial Disclosure Statements:
As a continuing medical education provider accredited by the ACCME, it is the policy of Pri Med Institute to require any individual in a position to influence educational content to disclose the existence of any financial interest or other personal relationship with the manufacturer(s) of any commercial product(s).

Badge Correction/Lost Badges:
If you have lost your badge, forgotten to bring your badge or the badge has been prepared incorrectly, please go to the On-Site Registration area where a new badge will be prepared.
Lost & Found:
Dana-Farber Cancer Institute, Pri-Med Institute and M|C Communications, LLC are not responsible for lost or misplaced belongings. Please be sure to remove all personal items from the session room at the end of each day. Any items left in the session room will be brought to the hotel lost and found.

CE Certificate Process:
1. Please locate the evaluation form for Day #1 of the program in the back pocket of the syllabus. There is one evaluation for each day of continuing education offered. You will be provided with a separate evaluation form for Day #2 when you check in at the registration table tomorrow morning. Fill out only those sections of the evaluation for which you attend.
2. Put your name and badge number on all evaluation forms.
3. Designate the type of credit you seek and sign. Please do not fill out more than one certification statement.
4. Be sure to fill out the amount of credit you are claiming within the certification statement. The amount of credit being sought must coincide with the session evaluations completed; please use the following table as a guide:

<table>
<thead>
<tr>
<th>Track Number or session title</th>
<th>AMA category 1 credit hours that the track is certified for:</th>
<th>*AMA category 1 credit hours that you will be eligible to receive if you attend:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.25</td>
<td>Track 1</td>
</tr>
<tr>
<td>2</td>
<td>4.25</td>
<td>Track 1-2</td>
</tr>
<tr>
<td>Comparative Effectiveness in Oncology Practice</td>
<td>.50</td>
<td>Comparative Effectiveness in Oncology Practice</td>
</tr>
<tr>
<td>3</td>
<td>4.25</td>
<td>Track 1-3</td>
</tr>
<tr>
<td>4</td>
<td>4.25</td>
<td>Track 1-4</td>
</tr>
</tbody>
</table>

* If you attend consecutive tracks please defer to the second column to determine cumulative credit amount.

5. Before you leave the program, hand in your evaluation materials to a staff member at the registration table. Time-stamped evaluation forms will be accepted by mail if postmarked within five (5) business days of the program’s completion. Unfortunately, we cannot accept evaluation forms by fax.
6. Within 4 weeks following the program, certificates will be posted online at www.dana-farber.pri-med.com (log in to your account and visit the CME Tracker to print out a copy of your certificate).
7. If you have questions about, or corrections to, your certificate after you have downloaded it, please call:

1-877-878-3388

Copyright notice:
No part of the Dana-Farber Master Class syllabus may be reproduced or otherwise incorporated into any information retrieval system, without the written permission of Pri-Med Institute, a division of M|C Holding Corporation.

The opinions, ideas, recommendations and perspectives expressed in the syllabus and accompanying presentations for Dana-Farber Master Class are those of the faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Dana-Farber Cancer Institute, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, M|C Communications, LLC, or commercial supporters. Clinical judgment must guide each clinician in weighing the benefit of any diagnostic intervention or treatment approach or intervention against the risk of the intervention or treatment. Dosage, indications and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience or expertise of the individual faculty speaker. Any diagnostic procedures or treatments should not be utilized by clinicians or other healthcare professionals without evaluation of their patients' conditions, and of possible contraindications or risks and without a review of any applicable manufacturer's product information and comparison with the recommendations of other authorities.
Welcome to Dana-Farber Master Class for Oncologists, the next generation of continuing education for oncologists. We conceived of the program as a way to reinvent how oncologists learn and access knowledge about the latest advances and innovations in treatment.

Master Class curriculum includes online CME activities developed by the faculty to expand upon today’s sessions. These activities are designed to enhance your knowledge before and after attending the program.

Online CME Activities

A variety of new expert perspective articles, case studies, and multimedia lectures are added to www.dfci.pri-med.com on an ongoing basis, so visit the web site frequently. Current activities include:

**Robert J. Mayer, MD**, Expert Perspective
Clinical Trial Update: Combining Targeted Therapies in Metastatic Colorectal Cancer

**Eric P. Winer, MD**, Webcast
Treatment of HER2 Positive Breast Cancer

**Richard M. Stone, MD**, Expert Perspective
Acute Myeloid Leukemia: Impact of Genetics on Prognosis

**Bruce E. Johnson, MD**, Expert Perspective
Extensive-Stage Small Cell Lung Cancer: Is Irinotecan/Cisplatin a Viable Alternative?

**Ann LaCasce, MD**, Case Study
55-Year-Old Man Presents for Evaluation of Recently Diagnosed Mantle Cell Lymphoma (MCL)

CME on iTunes

Now you can listen to audio recordings of Master Class Webcasts on your iPod or MP3 player. The CME Podcast Series makes earning online CME easy and enjoyable.

Recently added:
Dr Eric Winer’s Webcast: Treatment of HER2 Positive Breast Cancer
Dr Mark Kris’s Webcast: Primary Treatment of Non-Small Cell Lung Cancer
Dr Alan Venook’s Webcast: Pancreatic and Hepatobiliary Cancers: Progress at Last?

Visit www.pri-med.com/dfpodcasts for the full listing.
Get your CME certificates faster with MY CME Planner/Tracker online.

Our CME tracker lets you:

- Store an electronic library of your CME certificates
- Print and download your certificate as soon as it’s ready
- Print a summary of credits earned to submit to licensing board

Listen to Master Class Webcasts on iTunes.

Now you can listen to audio recordings of Dana-Farber Webcasts on your iPod or MP3 player. Visit www.Dana-Farber.Pri-Med.com/DFpodcasts for details.

Dana-Farber Cancer Institute has partnered with Pri-Med Institute®, a leading accredited CME provider, to help develop the educational conference and online programs. All certificates for this program can easily be obtained via the www.Dana-Farber.Pri-Med.com Web site.

Getting your CME certificate from today’s program is easier than ever. By visiting www.Dana-Farber.Pri-Med.com, you can quickly see what credits you’ve earned, and then print or save your certificates.

How does it work? We simply send you an e-mail when your certificate is online and ready to print. See other side for easy instructions on how to print your certificate(s).

Check out your CME Tracker today:
www.Dana-Farber.Pri-Med.com
HOW TO PRINT YOUR CERTIFICATE IN 3 EASY STEPS:


2. Log in using your username and password*.

   * Our improved “Forgot My Password” management can help you retrieve a forgotten username or password.

3. Once logged in, you’ll see your “Summary of Credits Earned.” Click on “Print Certificate.” After opening your certificate, you can print it and/or save it to your computer.
MASTER CLASS FOR ONCOLOGISTS:

HEMATOLOGIC MALIGNANCIES TRACK
HEMATOLOGICAL MALIGNANCIES TRACK

Hematological Malignancies Track Learning Objectives

Oncologists will:

1. Use new information on the role of patient characteristics, clinical findings, and genetic data to improve their competencies in selecting treatment options for patients with acute leukemia and myelodysplastic syndromes.

2. Discuss current clinical evidence on therapeutic options for different types of myelodysplastic neoplasms based on proper diagnosis and accurate risk assessment, and describe how they will use this information to address gaps in their own clinical practices.

3. Describe how recent evidence on the use of prognostic factors such as age in selecting therapies for lymphomas will change their management strategies for these malignancies. Assess their clinical practices relative to the appropriate choice of initial therapies for each type and subtype of lymphoma, including consideration of systemic therapies and the role of autologous stem cell transplant.

4. Discuss specific steps that can be taken to incorporate current clinical evidence and expert recommendations on novel therapies into their clinical practices for the management of multiple myeloma.

5. Describe new and emerging therapies for chronic myelogenous leukemia and list specific recommendations for incorporating these therapies into current management strategies.

Faculty

Session 1: Recent Advances in the Understanding and Treatment of Acute Leukemia and Myelodysplastic Syndromes
7:30 AM – 8:15 AM

Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Director, Adult Leukemia Program
Dana-Farber Cancer Institute

Richard Maury Stone, MD, is director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, an attending physician at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School in Boston, Massachusetts.

Dr Stone cares for patients with acute and chronic leukemias, myelodysplasia, and myeloproliferative disorders. Dr Stone conducts clinical and translational research with the goal of deriving better outcomes for patients with these disorders. His laboratory research focuses on the mechanism of leukemic cell differentiation, with the ultimate goal of producing new cancer therapies. Dr Stone earned his AB in biochemistry at Harvard Medical College in Cambridge, Massachusetts and his MD at Harvard Medical School in Boston. After graduating, he completed his internship and residencies in internal medicine at Brigham and Women’s Hospital in Boston, where he was designated chief medical resident. Dr Stone trained as a Fellow in Medical Oncology at the Dana-Farber Cancer Institute.
Dr Stone is a recipient of the American Cancer Society Clinical Career Development Award, the National Institutes of Health (NIH) Clinical Investigator Award, Upjohn Outstanding Achievement in Cancer Research, and NIH FIRST Award. He serves as vice-chair of the Leukemia Committee of the National Cancer Cooperative Trials Group, Cancer and Leukemia Group B (CALGB). Dr Stone is a member of the Medical Oncology Board of the American Board of Internal Medicine and serves as chairman of the Medical Advisory Board for the International Aplastic Anemia and Myelodysplastic Syndrome Foundation, a patient advocacy group. Dr Stone’s articles, which are primarily devoted to leukemia and related topics, are published in prestigious journals such as Blood, the Journal of Clinical Oncology, Nature Genetics, and The New England Journal of Medicine, among others.

**Session 2: Chronic Myelocytic Leukemia: Imatinib and Beyond**
8:15 AM – 9:00 AM

**Daniel J. DeAngelo, MD, PhD**  
Associate Professor of Medicine  
Harvard Medical School  
Hematologic Malignancies Program  
Dana-Farber Cancer Institute

Daniel J. DeAngelo, MD, PhD, is the clinical director of the Adult Leukemia Program at Dana-Farber Cancer Institute (DFCI). He is also an associate professor in the Department of Medicine at Harvard Medical School and an attending physician at Brigham and Women’s Hospital (BWH). Dr DeAngelo maintains a large academic clinical practice, which is responsible for the diagnosis and treatment of patients with acute and chronic leukemia, myelodysplasia, and other stem cell hematopoietic disorders. His current research interests include novel immunotherapeutic approaches to the treatment of acute myelogenous leukemia and myelodysplasia, and he is currently developing leukemia tumor vaccines from patients with AML or advanced myelodysplasia.

Dr DeAngelo is a member of the National Comprehensive Cancer Network and the World CML Registry Steering Committee for Novartis. He has been an invited lecturer to several national and international conferences and has won multiple teaching awards including the Medical Oncology Education Award and the Lee Nadler Extra Mile Award, both from DFCI.

Dr DeAngelo received his BS from University of California at Berkeley. He graduated with an MS, MD, and PhD from the Albert Einstein College of Medicine at Yeshiva University. His residency was completed at Massachusetts General Hospital and he completed fellowships at both DFCI and BWH.
Session 3: Myeloproliferative Neoplasms:
Bringing Order to Complexity and Achieving Optimal Outcomes
9:15 AM – 10:00 AM

Ayalew Tefferi, MD
Professor of Medicine and Hematology
Mayo Medical School

Dr Ayalew Tefferi was born in Addis Ababa, Ethiopia and migrated to the United States in 1982 after completing his medical school education at the University of Athens in Athens, Greece. Dr Tefferi received his hematology training at the Mayo Clinic in Rochester, Minnesota before joining the staff at the Mayo Clinic College of Medicine, Division of Hematology in the Department of Medicine. He is currently a full professor in hematology and internal medicine.

Dr Tefferi is primarily engaged in direct patient care. His clinical and laboratory interests focus on myeloid disorders including polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, acute leukemia, and the atypical myeloproliferative disorders including hypereosinophilic syndrome and systemic mastocytosis. His academic and research achievements have been copious and include over 800 publications including books, book chapters, original articles, reviews, editorials, letters, and abstracts. Dr Tefferi serves as an associate or section editor for the Mayo Clinic Proceedings, Leukemia, American Journal of Hematology, and European Journal of Hematology. He also participates in the editorial board of several journals including Blood, Cancer, Leukemia Research, Acta Haematologica, and Leukemia and Lymphoma. Dr Tefferi has given more than 500 national and international invited lectureships and serves as faculty for the annual Hematology and Oncology Board review courses at George Washington University in Washington DC, Harvard in Boston, Massachusetts, and MD Anderson Cancer Center in Houston, Texas.

Session 4: Lymphomas: Optimizing Therapeutic Choices for Initial Management
10:00 AM – 10:45 AM

Track Director

Arnold S. Freedman, MD
Associate Professor of Medicine
Harvard Medical School

Clinical Director, Lymphoma Program
Dana-Farber Cancer Institute

Arnold Freedman, MD, is an associate professor of medicine at Harvard Medical School and at Dana-Farber Cancer Institute (DFCI) in the Department of Medical Oncology and attending physician at Brigham and Women’s Hospital. He is the clinical director of the Lymphoma Program at DFCI. Dr Freedman has focused on clinical and laboratory research in non-Hodgkin’s lymphomas. A graduate of Brandeis University, Dr Freedman received his
MD from University of Massachusetts Medical School, and came to Dana-Farber as a fellow in medical oncology in 1982.

Dr Freedman’s research interests have focused on the development of new therapies for non-Hodgkin’s lymphoma. This includes efforts are toward enhancing the effects of antibody based therapies and understanding how the tumor microenvironment can be manipulated in the treatment of lymphomas.

**Session 5: Multiple Myeloma: Current Treatment Paradigms and Future Directions**  
11:00 AM – 11:45 AM

*Kenneth C. Anderson, MD*  
Kraft Family Professor of Medicine  
Harvard Medical School  
Chief, Division of Hematologic Neoplasia and Director  
Jerome Lipper Multiple Myeloma Center  
Dana-Farber Cancer Institute

Dr Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at John’s Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School and serves as chief of the Division of Hematologic Neoplasia, director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute. He serves as chair of the National Comprehensive Cancer Network (NCCN) Multiple Myeloma Clinical Practice Guidelines Committee, as a Cancer and Leukemia Group B Principal Investigator, on the Board of Scientific Advisors of the International Myeloma Foundation, on the Board of Directors and as chair of the Scientific Advisory Board of the Multiple Myeloma Research Foundation, and on the Board of Directors and as chair of the Steering Committee of the Multiple Myeloma Research Consortium. He has published more than 350 original articles, 250 chapters, and has edited multiple textbooks on both multiple myeloma and on transfusion medicine. He is a Doris Duke Distinguished Clinical Research Scientist and has had long-term RO-1, PO-1, and Specialized Program of Research Excellence (SPORE) National Institutes of Health funding. His numerous awards include the 2001 Charles C. Lund Award of the American Red Cross Blood Services, the 2003 Waldenstrom’s award for research in plasma cell dyscrasias, the 2004 Johnson & Johnson Focused Giving Award for Setting New Directions in Science and Technology, the 2005 the Robert A. Kyle Lifetime Achievement Award, the 2007 American Association for Cancer Research Joseph H. Burchenal Award for Clinical Research, the 2007 ROFEH Distinguished Service Award for providing compassionate patient care internationally, and a 2007 Champion in Advocacy Award from the American Society of Hematology. He was named editor in chief of *Clinical Cancer Research* in 2007. In 2008 he received the Dameshek Prize from the American Society of Hematology.

Over the last two decades, he has focused his translational research studies on B-cell malignancies, especially multiple myeloma. Highlights of his contributions to science and medicine include: discovery of the first plasma cell reactive monoclonal antibodies; development of an immunophenotyping model for diagnosis and treatment of B-cell malignancies; pioneering novel methods to improve safety and efficacy of autografting and allografting in myeloma; characterizing the signaling cascades whereby cytokines mediate myeloma cell growth, survival, and drug resistance in the bone marrow microenvironment; using oncogenomics and developing in vitro and in vivo models to both identify novel targets and validate therapies targeting the myeloma cell and its bone marrow milieu; translating these preclinical studies to the bedside in derived phase 1-3 clinical trials; and establishing a new treatment paradigm using novel therapies targeting the tumor cell, tumor-host bone marrow interaction, and bone marrow microenvironment to overcome drug resistance and improve patient outcome in myeloma. His team led both preclinical and clinical trials of the novel proteasome inhibitor bortezomib, as well as the immunomodulatory
drug lenalidomide, culminating in the rapid FDA approval of these agents for treatment of myeloma. His paradigm for identifying and validating targets in the tumor cell and its milieu has therefore already provided novel therapies which have transformed myeloma therapy and offers great promise to improve patient outcome in hematologic malignancies and solid tumors as well.

Hematologic Malignancies Panel Discussion
11:45 AM – 12:15 PM

Faculty Financial Disclosure Statements
The presenting faculty reported the following:

Dr Stone serves as a consultant for Genzyme, Sunesis, and Eleos.
Dr DeAngelo serves on the speakers bureaus of Bristol-Myers Squibb, Celgene, Enzon Pharmaceuticals, and Novartis Pharmaceuticals Corporation.
Dr Tefferi has no relationships to disclose.
Dr Freedman has no relationships to disclose.
Dr Anderson receives consultant and research honoraria from Celgene Corporation, Novartis Pharmaceuticals Corporation, and Millennium Pharmaceuticals.

Drug List

<table>
<thead>
<tr>
<th>Generic</th>
<th>Trade</th>
</tr>
</thead>
<tbody>
<tr>
<td>arsenic trioxide</td>
<td>Trisenox</td>
</tr>
<tr>
<td>bendamustine</td>
<td>Treanda</td>
</tr>
<tr>
<td>bortezomib</td>
<td>Velcade</td>
</tr>
<tr>
<td>busulfan</td>
<td>Busulfex, Myleran</td>
</tr>
<tr>
<td>clofarabine</td>
<td>Clofarabine</td>
</tr>
<tr>
<td>dasatinib</td>
<td>Sprycel</td>
</tr>
<tr>
<td>decitabine</td>
<td>Dacogen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Generic</th>
<th>Trade</th>
</tr>
</thead>
<tbody>
<tr>
<td>deferasirox</td>
<td>Exjade</td>
</tr>
<tr>
<td>doxorubicin hydrochloride</td>
<td>Doxil</td>
</tr>
<tr>
<td>gemtuzumab ozogamicin</td>
<td>Mylotarg</td>
</tr>
<tr>
<td>imatinib</td>
<td>Gleevec</td>
</tr>
<tr>
<td>lenalidomide</td>
<td>Revlimid</td>
</tr>
<tr>
<td>rituximab</td>
<td>Rituxan</td>
</tr>
<tr>
<td>thalidomide</td>
<td>Thalomid</td>
</tr>
<tr>
<td>tretinoin</td>
<td>Vesanoid</td>
</tr>
</tbody>
</table>

Suggested Reading List


MASTER CLASS FOR ONCOLOGISTS:

BREAST CANCER TRACK
BREAST CANCER TRACK

Breast Cancer Track Learning Objectives

Oncologists will:

1. Identify the optimal combinations of targeted therapies with chemotherapeutic agents in human epidermal growth factor receptor-2 (HER2)-positive breast cancer, as determined by clinical evidence and expert guidance.
2. Assess their own clinical practices relative to the factors affecting choice and timing of adjuvant endocrine therapies in hormone receptor-positive breast cancer.
3. Define the impact of genetic status on breast cancer management as it relates to their clinical practices, including preventive care in high-risk patients and the choice of chemotherapeutic agents if cancer develops.
4. Describe current prognostic uses for the information about breast tumor heterogeneity revealed by molecular diagnostics testing and define specific changes in their performance to incorporate this information into their own clinical practice.
5. List appropriate follow up measures for breast cancer survivors, including surveillance for and management of recurrence and potential late or long term effects of cancer and cancer treatments, and formulate specific steps to incorporate these measures into their clinical practice.

Faculty

Session 1: Towards Personalized Medicine in Breast Cancer: Understanding Molecular Subsets and the Role of Diagnostics
1:00 PM – 1:45 PM

Lisa A. Carey, MD
Associate Professor of Medicine
University of North Carolina Medical School
Medical Director
UNC Breast Center
University of North Carolina Lineberger Comprehensive Cancer Center

Dr Carey graduated from Wellesley College in 1984 with a BA in biology and art history, before receiving an MS in physiology from the University of Kentucky. She received an MD from the Johns Hopkins University School of Medicine in 1990. After a residency in internal medicine also at Johns Hopkins, she stayed at Johns Hopkins for a fellowship in medical oncology. During her fellowship she completed a ScM in clinical research. Dr Carey joined the University of North Carolina (UNC) faculty in 1998. She has served since 2003 as the medical director of the UNC Breast Center and is the UNC-Lineberger Comprehensive Cancer Center (UNC-LCCC) Protocol Office Executive Committee Breast Disease Group Leader as well as the UNC-LCCC Protocol Review Committee Breast Cancer Chair.

Dr Carey has a well-defined interest in clinical/translational research in breast cancer, with a particular interest in the clinical implications of different molecular subtypes of breast cancer. She both designs and leads clinical trials as well as working often and well with laboratory investigators. She has successfully translated bench efforts from laboratory science collaborators into clinical research. She was the lead author of a recently published article in JAMA examining racial disparities among breast cancer molecular subtypes. She is the principal investigator (PI) of several clinical trials, including a multicenter inter-SPORE (Specialized Program of Research Excellence, National Cancer Institute [NCI]) Phase II study of targeted therapy in metastatic basal-like breast cancer (a subtype identified by gene expression array). This heavily funded trial includes both clinical and laboratory participation from the University of California, San Francisco; Dana Farber; Duke University; Georgetown; Johns Hopkins; Baylor;
Washington University; University of Alabama-Birmingham; Mayo; and M.D. Anderson Cancer Center, and is a testament to her ability to provide clinical leadership in translational and early clinical research. She is the PI of a recently published multicenter phase II study incorporating biologic therapy into chemotherapy for locally advanced breast cancer as well as a proposed cooperative group neoadjuvant trial examining several HER2-targeted strategies for Stage II-III HER2-positive breast cancer. She is the clinical liaison for several correlative science collaborations, including both institutional and cooperative group trials that correlate nucleic acid and protein characterization of breast cancers with response to neoadjuvant therapy. Dr Carey has served on the American Society of Clinical Oncology (ASCO) Scientific Program Committee and as faculty for the ASCO annual meeting for several years. She was named to the Cancer and Leukemia Group B (CALGB) Breast Core Committee in 2003. She was awarded a Doris Duke Clinician Scientist Award in 1999 and a Career Development Award from the NCI in 2000.

Session 2: Genetic Testing in Breast Cancer:  
Appropriate Patient Selection and Implications for Management  
1:45 PM – 2:30 PM

Judy E. Garber, MD, MPH  
Associate Professor of Medicine  
Harvard Medical School  
Director, Cancer Risk and Prevention Program  
Dana-Farber Cancer Institute

Judy E. Garber, MD, MPH, is director of the Cancer Risk and Prevention Program at the Dana-Farber Cancer Institute. She is attending physician at Dana-Farber’s Breast Oncology Center, an associate physician at Brigham and Women’s Hospital and an associate professor of medicine at Harvard Medical School. Dr Garber’s research is focused on genetic susceptibility to breast, ovarian and other cancers, and the development of novel medical strategies to prevent cancer.

Session 3: HER2+ Breast Cancer: Current Best Practices and Future Directions  
2:45 PM – 3:30 PM

Eric P. Winer, MD  
Professor of Medicine  
Harvard Medical School  
Chief, Division of Women’s Cancers  
Dana-Farber Cancer Institute

Eric P. Winer, MD, is chief, Division of Women’s Cancers, and the Thompson Senior Investigator in Breast Cancer Research at Dana-Farber Cancer Institute. He is also a professor of medicine at Harvard Medical School. Dr Winer received his undergraduate and medical degrees from Yale University. After completing internal medicine and medical oncology training at Yale and Duke, he was on the faculty at Duke Medical Center for 8 years before moving to Dana-Farber Cancer Institute in 1997. Dr Winer is widely published, having authored over 200 articles, clinical communications, reviews, book chapters, and editorials. He serves on the editorial board for several peer-reviewed publications, including the *Journal of Clinical Oncology* and *Breast Cancer Research and Treatment*. Dr Winer is co-chair of Cancer and Leukemia Group B (CALGB) Breast Committee. Dr Winer is the current chair of the American
Society of Clinical Oncology’s Cancer Communications Committee. Dr Winer is also the Chief Scientific Advisor and Chair of the Scientific Advisory Board for Susan G. Komen for the Cure.

**Session 4: Adjuvant Endocrine Therapy: Therapeutic Choices and Factors Affecting Recurrence in Hormone Receptor–Positive Breast Cancer**

3:30 PM – 4:15 PM

**Track Director**

**Harold J. Burstein, MD, PhD**

Associate Professor of Medicine
Harvard Medical School

Breast Oncology Center
Dana-Farber Cancer Institute

Harold J. Burstein, MD, PhD, is an associate professor of medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women’s Hospital. He is a clinician and clinical investigator specializing in breast cancer.

Dr Burstein attended Harvard College and earned his MD at Harvard Medical School, where he also earned a PhD in immunology. In addition, he holds a master’s degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital, and was a fellow in medical oncology at Dana-Farber before joining the staff.

Dr Burstein’s clinical practice is devoted entirely to breast cancer patients. His clinical research interests include novel treatments for early- and advanced-stage breast cancer and studies of quality of life and health behavior among women with breast cancer. Dr Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications of Dr Burstein’s can be found in the *New England Journal of Medicine*, the *Journal of Clinical Oncology*, and other leading medical journals. With Dr Gary Lyman, he is co-editor of the book *Translational Therapy for Breast Cancer*, published in 2007. He has served or is serving on international committees focusing on cancer treatments such as the National Comprehensive Cancer Network Breast Cancer Panel, The St. Gallen Breast Cancer Panel, the Cancer and Leukemia Group B (CALGB) Breast Cancer Committee, the American Society of Clinical Oncology (ASCO) Health Services Research and Clinical Research Committees, the National Quality Forum Breast Cancer Technical Panel, and several ASCO expert panels related to breast cancer. He teaches students, house staff, and fellows at Harvard Medical School, Dana-Farber, Brigham & Women’s Hospital, and affiliated training hospitals.
Session 5: Breast Cancer Survivorship: Optimizing Patient Follow-up for Recurrence and Late or Long-Term Effects of Therapy
4:30 PM – 5:15 PM

Ann H. Partridge, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute

Ann Partridge, MD, MPH, is an assistant professor of medicine at Harvard Medical School and serves as the clinical director of the Breast Oncology Center at the Dana-Farber Cancer Institute. She also founded and directs the Program for Young Women with Breast Cancer at Dana-Farber Cancer Institute to address the needs of women in their early 40s and younger. Through this unique multidisciplinary program, Dr Partridge and her colleagues aim to provide comprehensive care and support to young women at every step of their journey beginning with diagnosis through treatment and survivorship.

Dr Partridge’s clinical research focuses on psychosocial, communication, and survivorship issues in breast cancer, with a particular interest in improving the care and outcomes for young women with breast cancer. Dr Partridge has published several manuscripts and chapters related to breast cancer care and survivorship issues. She lectures nationally and internationally on issues related to young women with breast cancer, and serves as a member of the American Society of Clinical Oncology (ASCO) Survivorship Task Force, Fertility Preservation Guidelines Committee, and Health Services Committee. She is also co-chair of the Cancer and Leukemia Group B (CALGB) Committee on Advocacy, Research Communication, and Ethics (CARE) Committee. She has received awards and grants for her research including an ASCO Career Development Award, Tracy Starr Breast Cancer Research Fund Award, and Lance Armstrong Foundation Cancer Survivorship Award. Dr Partridge graduated from Georgetown University, earned her MD at Cornell University, trained in internal medicine at the Hospital of the University of Pennsylvania, and completed hematology and medical oncology fellowships at Dana-Farber Cancer Institute. She also received a master’s degree in public health at the Harvard School of Public Health.

Breast Cancer Panel Discussion
5:15 PM – 5:45 PM

Faculty Financial Disclosure Statements
The presenting faculty reported the following:

Dr Carey serves as a consultant for Eli Lilly and Company, Wyeth Pharmaceuticals, BiPar, and sanofi-aventis U.S. She receives research grants from Genentech, GlaxoSmithKline, Genomic, Novartis Pharmaceuticals Corporation, and Bristol-Myers Squibb.
Dr Garber serves as an investigator for Wyeth Pharmaceuticals, Novartis Pharmaceuticals Corporation, and AstraZeneca Pharmaceuticals LP.
Dr Winer has no relationships to disclose.
Dr Burstein has no relationships to disclose.
Dr Partridge has no relationships to disclose.
<table>
<thead>
<tr>
<th>Drug List</th>
<th>Genetic</th>
<th>Trade</th>
</tr>
</thead>
<tbody>
<tr>
<td>albumin-bound paclitaxel for injection</td>
<td>abraxane</td>
<td>Abraxane</td>
</tr>
<tr>
<td>anastrozole</td>
<td>aromadex</td>
<td>Arimidex</td>
</tr>
<tr>
<td>bevacizumab</td>
<td>avastin</td>
<td>Avastin</td>
</tr>
<tr>
<td>capecitabine</td>
<td>xeloda</td>
<td>Xeloda</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genetic</th>
<th>Trade</th>
</tr>
</thead>
<tbody>
<tr>
<td>cetuximab</td>
<td>erbitux</td>
</tr>
<tr>
<td>docetaxel</td>
<td>taxotere</td>
</tr>
<tr>
<td>exemestane</td>
<td>aromasin</td>
</tr>
<tr>
<td>lapatinib</td>
<td>tykerb</td>
</tr>
<tr>
<td>letrozole</td>
<td>femara</td>
</tr>
<tr>
<td>trastuzumab</td>
<td>herceptin</td>
</tr>
</tbody>
</table>

Suggested Reading List


MASTER CLASS FOR ONCOLOGISTS:

COMPARATIVE EFFECTIVENESS AND MEDICAL ONCOLOGY PRACTICE
Comparative Effectiveness and Medical Oncology Practice

Learning Objectives

Oncologists will:
1. Understand comparative effectiveness initiatives that are part of the 2009 stimulus and how they may impact on oncology practice.

Comparative Effectiveness in Oncology Practice
6:15 PM – 6:45 PM

Deborah Schrag, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Outcomes and Policy Research
Dana-Farber Cancer Institute

Dr Deborah Schrag received her medical degree from Columbia University College of Physicians and Surgeons in New York in 1991. She subsequently completed her residency in internal medicine at Brigham and Women’s Hospital and her fellowship in medical oncology at Dana-Farber Cancer Institute (DFCI). She obtained a master’s degree in public health from the Harvard School of Public Health in 1998. From 1999 through 2007, Dr Schrag practiced medical oncology in the Division of Gastrointestinal Oncology at Memorial Sloan-Kettering Cancer Center, where she was an associate member and associate professor of public health and medicine. In 2008, she returned to DFCI and Brigham and Women’s Hospital, where she is a medical oncologist in the Gastrointestinal Cancer Center and a health services researcher in the Center for Outcomes and Policy Research. She is an associate professor of medicine at the Harvard Medical School. She serves as a board member of the American Society of Clinical Oncology and a director for the American Board of Internal Medicine.

Faculty Financial Disclosure Statement
The presenting faculty reported the following:

Dr Deborah Schrag has no relationships to disclose.
MASTER CLASS FOR ONCOLOGISTS:

GASTROINTESTINAL CANCERS TRACK
GASTROINTESTINAL CANCERS TRACK

Gastrointestinal Cancers Track Learning Objectives

Oncologists will be able to:

1. Describe recent clinical trial results on new and emerging agents for the treatment of metastatic esophageal or gastric cancers and how these results are likely to change their management practices for these cancers.
2. Summarize the options for treatment and prevention of recurrence in advanced pancreatic cancer and assess how well these options have been integrated into their current practices. List emerging treatment options for hepatocellular cancer and describe specific steps for incorporating these new options in their practices.
3. Demonstrate familiarity with current clinical evidence regarding the roles of chemotherapeutic and targeted agents and their combinations in the treatment of advanced colorectal cancer.
4. Describe patient characteristics that suggest the presence of a hereditary gastrointestinal cancer syndrome and discuss specific steps that should be taken once such a syndrome has been identified.
5. List dietary, lifestyle, and environmental factors currently thought to be associated with increased or decreased risk of developing colorectal cancer and delineate strategies for effectively communicating this information to their patients.

Faculty

Session 1: Update on Esophagogastric Cancers: Weighing the Therapeutic Options
7:30 AM – 8:15 AM

Peter C. Enzinger, MD
Assistant Professor of Medicine
Harvard Medical School
Clinical Director, Center for Gastrointestinal Oncology
Dana-Farber Cancer Institute

Peter C. Enzinger, MD, is the clinical director of the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute and is an assistant professor of medicine at Harvard Medical School, both in Boston, Massachusetts. Dr Enzinger received his undergraduate and medical degrees from Brown University. He completed his residency in internal medicine at the University of Rochester School of Medicine and Dentistry. Subsequently, he completed a fellowship in medical oncology and hematology at Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University in New York City. Dr Enzinger has published many original articles and reviews in journals such as the New England Journal of Medicine, Annals of Oncology, Annals of Surgery, Cancer, and Seminars of Oncology, and serves as a reviewer for the New England Journal of Medicine and many other medical journals. He is a member of the Dana-Farber/Harvard Cancer Center Scientific Review Committee, a grant reviewer for the FDA and National Comprehensive Cancer Network (NCCN), and a member of the National Cancer Institute--Gastrointestinal Intergroup--Esophago-Gastric Task Force, NCCN Colon/Rectal/Anal Cancers Panel, and American Society of Clinical Oncology Cancer Education Committee.
Alan P. Venook, MD  
Professor of Clinical Medicine  
University of California San Francisco Medical School  
Chief, Gastrointestinal Oncology  
University of California, San Francisco Cancer Center

Alan Venook, MD, is a professor of clinical medicine at the University of California, San Francisco, where he leads the Gastrointestinal Oncology clinical program. He is currently the chair of the Committee on Human Research and director of the Regulatory Knowledge and Support (RKS) Program, UCSF Clinical and Translational Science Institute.

A nationally recognized expert in colorectal and liver cancers, Dr Venook received a BA degree from Rutgers University in 1976 and graduated from the UCSF School of Medicine in 1980. He spent two years in the Public Health Service following internship, and completed his training in internal medicine at UC Davis and his hematology and oncology training at UCSF. He has been on the faculty at UCSF since 1988.

Dr Venook has served on the editorial board of the *Journal of Clinical Oncology* and is an ad hoc reviewer for numerous journals. He has served 3 times on the program committee for the annual ASCO meeting, chaired the Colorectal Cancer Program this year and is a member of the Gastrointestinal Cancer track at ASCO. He has published more than 60 original articles, chapters, or books dealing with gastrointestinal malignancies.

The focus of Dr Venook’s research is developing and refining methods of treating tumors in the liver with directed approaches, including infusional chemotherapy or biological agents. He is also an expert in the management of cancer patients with liver disease. He has conducted clinical trials to evaluate the activity of various chemical compounds in treating cancers of the liver, colon, and kidney.

Sapna Syngal, MD, MPH  
Associate Professor of Medicine  
Harvard Medical School  
Director, Familial Gastrointestinal Cancer Program  
Dana-Farber/Brigham and Women’s Cancer Center

Sapna Syngal, MD, MPH, is director of the GI Cancer Risk and Prevention Program at the Dana-Farber Cancer Institute. She is also an associate physician at the Department of Medicine at Brigham and Women’s Hospital and an associate professor of medicine at the Harvard Medical School. Dr Syngal’s research is focused on genetic susceptibility to colorectal and pancreatic cancers and medical strategies to prevent them. Dr Syngal joined the Dana-Farber Cancer Institute faculty in 1995, after completing fellowships in medicine at Harvard Medical and a clinical research fellowship in gastroenterology at the Brigham and Women’s Hospital. A graduate of McGill University and Harvard Medical School, Dr Syngal has been recognized nationwide for her expertise in genetics and gastrointestinal malignancies.
Session 4: Reducing Risk of Colorectal Cancer:  
Current Evidence on Dietary, Lifestyle, and other Factors  
10:00 AM – 10:45 AM

Charles S. Fuchs, MD, MPH  
Associate Professor of Medicine  
Harvard Medical School  
Director, Center for Gastrointestinal Oncology  
Dana-Farber Cancer Institute  
Director, Gastrointestinal Malignancy Program  
Dana-Farber/Harvard Cancer Center

Dr Fuchs is an associate professor of medicine at Harvard Medical School and director of both the Center for Gastrointestinal Oncology at the Dana-Farber Cancer Institute and the Gastrointestinal Malignancies Program for the Dana-Farber Harvard Cancer Center. He splits his time between clinical care, clinical research, and laboratory-based activities. His epidemiologic research focuses on environmental and genetic risk factors for colorectal and pancreatic cancer, and his laboratory assesses biochemical markers of gastrointestinal cancer risk, understanding molecular predictors of patient prognosis in colorectal and pancreatic cancers, and the discovery of novel targets for cancer therapy. In his capacity as a medical oncologist, Dr Fuchs focuses his work on the treatment of patients with gastrointestinal cancers and conducts clinical trials assessing novel targeted therapies for these malignancies. Dr Fuchs is a cadre member of GI Committee for Cancer and Leukemia Group B, and he is the director of Dana-Farber Harvard Specialized Program of Research Excellence (SPORE) Grant in Gastrointestinal Cancers. Dr Fuchs has over 240 scientific publications in such journals as The New England Journal of Medicine, Journal of the American Medical Association, Journal of Clinical Oncology, Cell, and Nature.

Session 5: Advances in the Systemic Treatment of Colorectal Cancer  
11:00 AM – 11:45 AM

Course Chair/Track Director

Robert J. Mayer, MD  
Stephen B. Kay Family Professor of Medicine  
Harvard Medical School  
Faculty Vice President for Academic Affairs  
Dana-Farber Cancer Institute

Dr Mayer is the faculty vice president for academic affairs at the Dana-Farber Cancer Institute, senior physician at the Brigham and Women’s Hospital, physician at the Massachusetts General Hospital, and the Stephen B. Kay Family Professor of Medicine at the Harvard Medical School, where he is also the faculty associate dean for admissions. He has directed the Institute's Medical Oncology Training Program since 1975 and is presently the director of the Hematology/Oncology Fellowship Program of Dana-Farber/Partners CancerCare. Dr Mayer’s research interests focus on gastrointestinal cancer, a subject about which he has published extensively. Dr Mayer founded the Center for Gastrointestinal Oncology at the Dana-Farber Cancer Institute and is the past chair of the Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B, a cooperative group sponsored by the National Cancer Institute. He has served as an associate editor for the New England Journal of Medicine, is a past president of the American Society of Clinical Oncology and the Association of Subspecialty Professors and is a former member of the Executive Committee of the American Board of Internal Medicine. Dr Mayer is a graduate of Williams College and the Harvard Medical School.
Gastrointestinal Cancer Panel Discussion
11:45 AM – 12:15 PM

Faculty Financial Disclosure Statements
The presenting faculty reported the following:

Dr Enzinger serves as a speaker/consultant for sanofi-aventis U.S., Pfizer Inc., Roche, Genentech, and ImClone/Bristol-Myers Squibb.
Dr Venook receives research grants from Genentech and Bayer-Onyx.
Dr Syngal has no relationships to disclose.
Dr Fuchs has no relationships to disclose.
Dr Mayer has no relationships to disclose.

<table>
<thead>
<tr>
<th>Drug List</th>
<th>Trade</th>
<th>Generic</th>
<th>Trade</th>
</tr>
</thead>
<tbody>
<tr>
<td>bevacizumab</td>
<td>Avastin</td>
<td>gemcitabine</td>
<td>Gemzar</td>
</tr>
<tr>
<td>capecitabine</td>
<td>Xeloda</td>
<td>irinotecan</td>
<td>Camptosar</td>
</tr>
<tr>
<td>cetuximab</td>
<td>Erbitux</td>
<td>oxaliplatin</td>
<td>Eloxatin</td>
</tr>
<tr>
<td>docetaxel</td>
<td>Taxotere</td>
<td>panitumumab</td>
<td>Vectibix</td>
</tr>
<tr>
<td>erlotinib</td>
<td>Tarceva</td>
<td>sorafenib</td>
<td>Nexavar</td>
</tr>
</tbody>
</table>

Suggested Reading List


National Cancer Institute: Adult Primary Liver Cancer Treatment. 2008.


MASTER CLASS FOR ONCOLOGISTS:
LUNG, HEAD, AND NECK CANCERS TRACK
LUNG, HEAD, AND NECK CANCERS TRACK

Lung, Head, and Neck Cancers Track Learning Objectives

Oncologists will:
1. Incorporate recent innovations in the surgical management of non-small cell lung cancer (NSCLC), including the use of minimally invasive techniques and multimodal treatment strategies, into their current management practices by applying expert faculty recommendations.
2. Enhance their competence and skills in the selection of appropriate therapeutic alternatives for high-risk NSCLC patients who have limited pulmonary reserves by making recommended practice changes. Make therapeutic choices for early stage, locally advanced, and advanced NSCLC that align with recent clinical evidence and expert recommendations as outlined in the educational activity.
3. Use alternative administration schedules, combination approaches and enhanced patient selection techniques to improve care for patients with relapsed NSCLC.
4. Improve standards of care for management of small cell lung cancer by applying tools and guidelines embedded in the educational activity to enhance clinical competence with therapeutic choices at each stage of the disease.
5. Incorporate expert recommendations for the use of surgery, chemotherapy, targeted therapies, and radiation into management strategies for patients at each stage of head and neck cancer, from localized to metastatic.

Faculty

Session 1: Innovations in the Surgical Treatment of Lung Cancer
1:00 PM – 1:45 PM

Scott J. Swanson, MD
Director, Minimally Invasive Thoracic Surgery Program
Brigham and Women’s Hospital

Chief Surgical Officer
Dana-Farber Cancer Institute

Lecturer on Surgery
Harvard Medical School

Dr Scott Swanson is director of the Minimally Invasive Thoracic Surgery Program at the Brigham and Women’s Hospital and chief surgical officer at the Dana Farber Cancer Institute. He was most recently chief of thoracic surgery at The Mount Sinai Medical Center and the Eugene W. Friedman, MD, Professor of Surgical Oncology. His current clinical focus includes all areas of thoracic oncology including lung cancer, esophageal cancer, and sarcoma.

Dr Swanson is the current editor of Sabiston and Spencer’s Surgery of the Chest and is involved with numerous societies within the field of thoracic surgery and oncology. He has authored over 100 peer-reviewed manuscripts, chapters, and educationally relevant publications.

Dr Swanson is the chairman of The Thoracic Subcommittee for Cancer and Leukemia Group B (CALGB). His research involves novel protocols for treatment of thoracic cancer and further elucidation of the molecular mechanisms of cancer.
Mark G. Kris, MD
Chief, Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University

Mark G. Kris, MD, is chief of the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center and attending physician at Memorial Hospital for Cancer and Allied Diseases, New York, New York. He is professor of medicine at the Weill Medical College of Cornell University and serves as co-leader of Memorial Sloan-Kettering’s Multidisciplinary Thoracic Disease Management Team. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology.

After receiving his medical degree from the Weill Medical College of Cornell University, he served as chief medical resident and fellow in medical oncology at Memorial Sloan-Kettering Cancer Center.

He is author or coauthor of 195 original scientific publications. Dr Kris holds memberships in the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He heads the Antiemetic Guideline Panel for the 2006 update for the American Society of Clinical Oncology. He is a member of the guideline panels on antiemetics and non-small cell lung cancer for the National Comprehensive Cancer Center Network. He serves as co-chair of the American Society of Clinical Oncology guideline panel for adjuvant chemotherapy and radiation for non-small cell lung cancer. In addition, he is a Fellow of the American College of Physicians and the American College of Chest Physicians. Dr Kris serves on the medical advisory board of Cancer Care, Inc. and The Joan’s Legacy Foundation.

Dr Kris is a specialist in thoracic malignancies (including lung cancer, thymoma, and neuroendocrine tumors arising in the chest). He is a clinical and translational investigator. His research includes: the evaluation of new anticancer agents, the development of treatments targeting lung cancer, multimodality therapy, the testing of antiemetics, and identifying better ways to manage the physical symptoms caused by cancer. He is particularly interested in developing strategies to select treatments for patients based on clinical factors and molecular characteristics of their tumor specimens.
Session 3: Improved Strategies for Relapsed NSCLC: New Regimens, New Combinations and Targeted Therapies
2:45 PM – 3:30 PM

Pasi A. Jänne, MD, PhD
Associate Professor of Medicine
Harvard Medical School

Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute

Dr Pasi A. Jänne is an assistant professor of medicine at Harvard Medical School and assistant physician at the Dana Farber Cancer Institute in Boston, Massachusetts. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002 he earned a master's degree in clinical investigation from Harvard University.

Dr Jänne’s research interests include investigation of oncogene mutations and how these correlate with clinical response to targeted therapies in lung cancer. Dr Jänne was one of the investigators who initially discovered EGFR mutations in 2004 and has subsequently studied their effect on clinical outcome of patients and on mechanisms of resistance. Dr Jänne has also worked on developing non–sequencing-based technology to detect mutations in EGFR and other oncogenes. Dr Jänne is a member of the Cancer and Leukemia Group B respiratory committee. He is also an active member of the American Society of Clinical Oncology, American Association for Cancer Research, European Society for Medical Oncology, and International Association for the Study of Lung Cancer. He was elected to the American Society of Clinical Investigation in 2008.

Session 4: Small Cell Lung Cancer: Best Practices and Recent Advances
3:30 PM – 4:15 PM

Track Director

Bruce E. Johnson, MD
Professor of Medicine
Harvard Medical School

Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute

Bruce E. Johnson, MD, is director of the Carole M. and Philip L. Lowe Thoracic Oncology Program at the Dana-Farber Cancer Institute (DFCI), director of the Dana-Farber/Brigham and Women’s Thoracic Oncology Program, and leader of the Dana-Farber/Harvard Cancer Center Lung Cancer Program that includes the 7 Harvard Medical School–affiliated institutions.

Dr Johnson is the principal investigator of the Dana-Farber/Harvard Cancer Center Specialized Program of Research Excellence (SPORE) in Lung Cancer, and holds the position of professor of medicine at the Brigham and
Women’s Hospital and Harvard Medical School. Dr Johnson earned his undergraduate degree at Harvard College and received his MD from the University of Minnesota in 1979. He completed his postgraduate training at the University of Chicago and the National Cancer Institute (NCI). After serving at NCI, where he was head of the Lung Cancer Biology Section, he joined The Dana-Farber Cancer Institute in 1999.

His laboratory-based research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies. His group was among those that discovered that patients with partial and complete responses to the epidermal growth factor receptor inhibitors gefitinib and erlotinib have mutations in the epidermal growth factor receptor. These discoveries have been licensed to Genzyme who provides testing to identify patients with lung cancers to help select the initial treatment for patients with advanced disease. Dr Johnson leads a research team that is applying these findings to the clinical treatment of patients with lung cancer.

Dr Johnson is active at the national and international level. He is currently chair of the biology subcommittee to the External Scientific Committee for the National Cancer Institute, National Human Genome Research Institute Pilot Project Characterizing Cancer Genomes. Dr Johnson was the chair for the Review Committee on Early Detection Research Network: Biomarkers Development Laboratory, National Cancer Institute. He served as chair of the American Society of Clinical Oncology (ASCO) Communications Committee in 2005 and became chair of the Education Committee in July 2007. He recently was elected to serve as a member of the ASCO Board of Directors. He serves as senior editor for Clinical Cancer Research and is on the editorial board for International Journal of Oncology and Journal of Clinical Oncology. He recently received the ASCO Cancer Foundation’s Translational Research Professorship. He was awarded the Tisch Family Outstanding Achievement Award in Translational and Clinical Research in Solid Tumors from the Dana-Farber Cancer Institute. Dr Johnson is a recognized expert in lung cancer, particularly small cell lung cancer. He was the chair of the committee that drafted the National Comprehensive Cancer Network Guidelines on the treatment of small cell lung cancer.

He is currently one of four project leaders of the World Health Organization’s Pathology Panel, who are redefining adenocarcinoma of the lung by integrating the different genetic markers into the different types of lung cancer including bronchioloalveolar adenocarcinoma.

Dr Johnson has authored over 145 original reports in peer-reviewed journals and more than 95 reviews, chapters and editorials.

Session 5: Head and Neck Cancer: Update on Comprehensive Management 4:30 PM – 5:15 PM

David G. Pfister, MD
Professor of Medicine
Weill-Cornell Medical College

Chief, Head and Neck Medical Oncology Service
Memorial Sloan-Kettering Cancer Center

Dr Pfister is an internationally recognized expert in the management of head and neck tumors. He is chief of the Head and Neck Medical Oncology Service and co-chair of the Head and Neck Cancer Disease Management Team at Memorial Sloan-Kettering Cancer Center; he holds the rank of professor of medicine at Weill Medical College of Cornell University. His research interests include the development and evaluation of combined modality, “organ preservation” therapies; prognostic risk stratification; drug development; and outcome/quality of care assessment. He is co-chair of the Recurrent/Metastatic Disease Task Force for the Head and Neck Cancer Steering Committee at the National Cancer Institute (NCI). Dr Pfister has also figured prominently in the development and assessment of clinical practice guidelines as a way to improve the quality of care within oncology, currently holding leadership positions both within the National Comprehensive Cancer Network (NCCN), where he serves on the Board of Directors, and the American Society of Clinical Oncology (ASCO). He is the current co-chair of ASCO’s Larynx
Preservation Guideline Panel, and former co-chair of the Society’s Unresectable Lung Cancer Guideline Panel. He is a former chair of ASCO’s Health Services Research Committee, as well as of the Program Committee’s, Head and Neck Cancer subcommittee. Dr Pfister serves on the editorial boards of the *Journal of Clinical Oncology, Clinical Cancer Research*, and *Critical Reviews in Oncology/Hematology*.

**Lung, Head, and Neck Cancers Panel Discussion**
*5:15 PM – 5:45 PM*

**Faculty Financial Disclosure Statements**
The presenting faculty reported the following:

Dr Swanson serves as a consultant for Ethicon.
Dr Kris serves as a consultant for Bristol-Myers Squibb, ImClone, and AstraZeneca LP.
Dr Jänne serves as a consultant for Roche and Boehringer Ingelheim Pharmaceuticals, Inc.; and AstraZeneca LP. He also receives royalties from Genzyme.
Dr Johnson serves as a consultant and receives patent honoraria from Genzyme.
Dr Pfister serves as an investigator and on the board of data safety monitoring for sanofi-aventis U.S. and as an investigator for AstraZeneca LP.

**Drug List**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Trade</th>
</tr>
</thead>
<tbody>
<tr>
<td>pemetrexed</td>
<td>Alimta</td>
</tr>
<tr>
<td>bevacizumab</td>
<td>Avastin</td>
</tr>
<tr>
<td>irinotecan</td>
<td>Camptosar</td>
</tr>
<tr>
<td>cetuximab</td>
<td>Erbitux</td>
</tr>
<tr>
<td>topotecan</td>
<td>Hycamnif</td>
</tr>
<tr>
<td>gefitinib</td>
<td>Iressa</td>
</tr>
<tr>
<td>erlotinib</td>
<td>Tarceva</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Generic</th>
<th>Trade</th>
</tr>
</thead>
<tbody>
<tr>
<td>docetaxel</td>
<td>Taxotere</td>
</tr>
<tr>
<td>panitumumab</td>
<td>Vectibix</td>
</tr>
<tr>
<td>vandetanib</td>
<td>Zactima</td>
</tr>
</tbody>
</table>

| Investigational | |
|-----------------||
| oblimersen      | Genasense  |
| paclitaxel poliglumex | Opaxio |

**Suggested Reading List**


